December 2015, Vol. 4, No. 6

← Back to Issue

Personalized Medicine in Oncology: Disseminating Essential Information

Letter to Our Readers

Dear Colleague,

Benson-pic-98pxOn behalf of all of us at Personalized Medicine in Oncology (PMO), I’d like to offer our warmest wishes to you this holiday season and our thanks for your loyal readership throughout 2015. Over this past year, we have witnessed advances in our knowledge of tumor biology, biomarkers, and immunotherapies that will ultimately improve our ability to effectively and safely treat patients with cancer.

With these advances, our editorial staff has added departments and enhanced existing ones to improve dissemination of this essential information. These include:

  • Interview with the Innovators Series: In each issue, we speak with people making a difference in the field of personalized medicine. From leading researchers and novel diagnostic companies to policy makers and patient organizations, these interviews provide insights to the trends in precision medicine
  • Genetic Counseling Column: 2015 saw the launch of our newest department authored by editorial board member Cristi Radford, MS, CGC, of the Moffitt Cancer Center. Ms Radford will address cutting-edge topics in this expanding field
  • The Last Word: PMO is a proud partner of the Personalized Medicine Coalition (PMC) and is pleased to host a regular column by the President of the PMC, Edward Abrahams, PhD. Dr Abrahams brings expertise in the policy trends affecting our ability to provide personalized care to our patients
  • PersonalizedMedOnc.com: An invaluable resource to our readers, our website includes articles from the journal as well as breaking news stories, conference correspondent highlights, special issues, and videos. I strongly encourage you to subscribe.

It is our continuing hope that our comprehensive services benefit you and ultimately your patients. Thank you for your readership and all the best to you in 2016.

Sincerely,

 

Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology

Genetic Counseling - December 28, 2015

Inherited Colorectal Cancer: POLE and POLD1

The association of POLE and POLD1 with colorectal cancer risk was demonstrated in 2013. Palles and colleagues studied families with a dominant pattern of inherited colorectal cancer and multiple adenomas through whole genome sequencing.1 Through these efforts, they identified germline mutations in POLE and POLD1 as high-penetrance genes predisposing to [ Read More ]

FDA Approvals, News & Updates - December 28, 2015

FDA Approves Opdivo to Treat Advanced Form of Kidney Cancer

On November 23, 2015, the FDA approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy. “Opdivo provides an important therapy option for patients with renal cell carcinoma,” said Richard Pazdur, MD, Director of [ Read More ]